Shopping Cart
Remove All
Your shopping cart is currently empty
P11 is a selective platelet-activating factor acetylhydrolase (PAFAH1b2 and PAFAH1b3) inhibitor, blocking PAFAH1b2/3-mediated hydrolysis of PAF to lysophosphatidic acid, used to study PAFAH1b2/3 cellular functions.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $113 | 35 days | 35 days | |
| 1 mg | $198 | 35 days | 35 days | |
| 5 mg | $833 | 35 days | 35 days | |
| 10 mg | $1,430 | 35 days | 35 days |
| Description | P11 is a selective platelet-activating factor acetylhydrolase (PAFAH1b2 and PAFAH1b3) inhibitor, blocking PAFAH1b2/3-mediated hydrolysis of PAF to lysophosphatidic acid, used to study PAFAH1b2/3 cellular functions. |
| Targets&IC50 | PAFAH1b2:0.8 μM |
| In vitro | P11 showed particularly good efficacy against PAFAH1b2 with an IC50 value of 0.8 μM; P11 blocks the hydrolysis of PAFAH1b2 and Pafah1B3-mediated substrate PAF to hemolytic PAF with IC50 values of 36 and 880 nM, respectively. [1] |
| Synonyms | PAFAH-1-b-2, PAFAH1b2, PAFAH 1 b 2, 3-IN-P11, 3INP11, 3 IN P11 |
| Molecular Weight | 503.65 |
| Formula | C30H33NO4S |
| Cas No. | 942285-55-4 |
| Smiles | S(=O)(=O)(N1[C@H](C(C(O)=O)=CC[C@H]1C2=CC=C(C)C=C2)C3=CC=C(C(C)(C)C)C=C3)C4=CC=C(C)C=C4 |
| Relative Density. | 1.210 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (79.42 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (3.97 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.